VERIMMUNE Trademark

Trademark Overview

On Tuesday, February 25, 2020, a trademark application was filed for VERIMMUNE with the United States Patent and Trademark Office. The USPTO has given the VERIMMUNE trademark a serial number of 88809441. The federal status of this trademark filing is REGISTERED as of Tuesday, July 19, 2022. This trademark is owned by VerImmune Inc.. The VERIMMUNE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development; medical research, namely, developing immune modulators for the prevention and treatment of cancer and tumors; research and development in the field of pharmaceutical preparations for immune modulators for the prevention and treatment of cancer and tumors
verimmune

General Information

Serial Number88809441
Word MarkVERIMMUNE
Filing DateTuesday, February 25, 2020
Status700 - REGISTERED
Status DateTuesday, July 19, 2022
Registration Number6798303
Registration DateTuesday, July 19, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 16, 2021

Trademark Statements

Goods and ServicesPharmaceutical research and development; medical research, namely, developing immune modulators for the prevention and treatment of cancer and tumors; research and development in the field of pharmaceutical preparations for immune modulators for the prevention and treatment of cancer and tumors

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, February 28, 2020
Primary Code042
First Use Anywhere DateWednesday, January 1, 2020
First Use In Commerce DateWednesday, January 1, 2020

Trademark Owner History

Party NameVerImmune Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressWashington, DC 20012
Party NameVerImmune Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWashington, DC 20012
Party NameVerImmune Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBaltimore, MD 21205

Trademark Events

Event DateEvent Description
Tuesday, July 19, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, July 19, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, June 14, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, June 13, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, June 9, 2022ASSIGNED TO EXAMINER
Monday, May 16, 2022STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 4, 2022USE AMENDMENT FILED
Friday, May 13, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, May 4, 2022TEAS STATEMENT OF USE RECEIVED
Saturday, November 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 11, 2021SOU EXTENSION 1 GRANTED
Thursday, November 11, 2021SOU EXTENSION 1 FILED
Thursday, November 11, 2021TEAS EXTENSION RECEIVED
Tuesday, May 11, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 16, 2021PUBLISHED FOR OPPOSITION
Wednesday, February 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 8, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, February 1, 2021EXAMINER'S AMENDMENT ENTERED
Monday, February 1, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, February 1, 2021EXAMINERS AMENDMENT E-MAILED
Monday, February 1, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, October 21, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, October 21, 2020FINAL REFUSAL E-MAILED
Wednesday, October 21, 2020FINAL REFUSAL WRITTEN
Monday, September 28, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 28, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 28, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 26, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 26, 2020NON-FINAL ACTION E-MAILED
Tuesday, May 26, 2020NON-FINAL ACTION WRITTEN
Thursday, May 14, 2020ASSIGNED TO EXAMINER
Friday, February 28, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, February 28, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

verimmune research prevention treatment tumors modulators cancer immune development pharmaceutical preparations